Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations

Authors

  • Morris Sherman M.B., B.Ch.,

    Corresponding author
    1. Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    • Department of Medicine, Toronto General Hospital, 585 University Avenue, Toronto, Ontario, Canada M5G 2N2===

    Search for more papers by this author
    • Potential conflict of interest: Dr. Bruix consults for and received grants from Sumitomo, Pharmexa, Aisa, Biocompatibles, Big Alliance, and Kowa. He advises and received grants from Bayer, Lilly, Novartis, ArQule, and Schering-Plough. Dr. Tran advises and received grants from Bristol-Myers Squibb. He also advises Gilad Sciences.

  • Jordi Bruix M.D.,

    1. Barcelona Clínic Liver Cancer Group, Liver Unit CIBERehd, Institut d'Investigacions BiomèdiquesAugust Pi i Sunyer, Hospital Clínic Barcelona Barcelona, Spain
    Search for more papers by this author
  • Michael Porayko M.D.,

    1. Division of Gastroenterology and Hepatology, Vanderbilt Medical Center, Nashville, Tennessee
    Search for more papers by this author
  • Tram Tran M.D.,

    1. Cedars Sinai Medical Center, Los Angeles, California
    Search for more papers by this author
  • for the AASLD Practice Guidelines Committee

    1. Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    Search for more papers by this author

  • fax: 416-591-2107

Ancillary